Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Cure8 research brief
Why This Matters
Patients and clinicians choosing induction therapy for moderate‑to‑severe ulcerative colitis may find comparative efficacy and safety data useful, especially when head‑to‑head trials are limited. The review highlights upadacitinib and several newer agents as high‑ranking options.
Who Should Pay Attention
Clinicians treating moderate-to-severe UC, gastroenterology researchers, and patients considering or switching advanced therapies (including those with prior biologic/JAK exposure).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is an abstract of a systematic review and network meta-analysis comparing induction efficacy and safety of advanced therapies for moderate-to-severe ulcerative colitis.
What the study did: The authors pooled phase 3 randomized trials (33 trials, 17 therapies) and used network meta-analysis to compare clinical remission, endoscopic improvement, and safety outcomes (serious adverse events, discontinuations, serious infections). Analyses were stratified by prior exposure to advanced therapies.
Key findings shown in the abstract: Upadacitinib ranked highest for clinical remission and endoscopic improvement overall and in both AT‑naïve and AT‑experienced subgroups. Other agents highlighted as effective included obefazimod (in AT‑naïve) and ustekinumab and tofacitinib (in AT‑experienced).
Anti‑p19 (IL‑23 p19) inhibitors (risankizumab, guselkumab, mirikizumab) were noted to have favorable safety profiles, though safety estimates had lower confidence.
How I read this for patients: This review summarizes many phase 3 trials and suggests upadacitinib is particularly effective for induction of remission in ulcerative colitis, with several other agents performing well depending on prior treatment history. Safety comparisons are more uncertain.
Keep In Mind
This entry is based on the article abstract (systematic review and NMA). Network meta-analyses combine indirect comparisons and rely on trial similarity; confidence varied by outcome and subgroup. The abstract does not provide full numeric details for all agents or long‑term safety data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
AuthorsPablo A Olivera, Juan S Lasa, Siddharth Singh +5 more
InstitutionDivision of Gastroenterology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedOct 6, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
NEW PERSPECTIVES IN THE TREATMENT OF ULCERATIVE COLITIS IN ADULTS - IL-23 INHIBITORS: EFFICACY AND SAFETY
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
Meta-analysis: safety and efficacy of ustekinumab in pediatric inflammatory bowel disease patients with anti-TNF failure.
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis
S1P receptor modulators are an emerging oral class of advanced therapy for moderate-to-severe ulcerative colitis; a systematic review that pools multiple RCTs helps clarify how effective and safe the class appears to be...